Get the Daily Brief
Latest Biotech News
Emerging AI and Digital Technologies Transforming Bioprocessing and Drug Discovery
Industry leaders are leveraging AI and data analytics to transform biologics development and drug discovery. Sanofi's iCMC digital transformation program employs data, machine learning, and...
Cancer Innovations Highlight Molecular Targets and Diagnostic Advances
Recent studies cover therapeutic and diagnostic advances in oncology. Natera presented improved survival data in Signatera-positive bladder cancer patients receiving Tecentriq, progressing towards...
Innovations in Neonatal and Pediatric Care Technologies
Groundbreaking technologies are shaping neonatal and pediatric medicine. Virtual reality simulation for neonatal resuscitation training has been piloted, combining immersion with life-saving...
Environmental and Agricultural Biotechnology: New Frontiers
Researchers are unveiling new biotechnologies aimed at environmental sustainability and agricultural innovation. University of Missouri-led studies reveal poplar trees dynamically regulate wood...
AI and Automation Transform Bioprocessing: Sanofi’s Vision for Bioprocessing 4.0
At the Bioprocessing Summit in Boston, Sanofi’s digital transformation lead, Cenk Undey, outlined the integration of AI, data analytics, and automation to revolutionize biologics manufacturing....
Liquid Biopsy Innovation: Myriad Genetics and Angle Team on Tumor Cell Detection
Angle has entered a research collaboration with Myriad Genetics to co-develop liquid biopsy assays leveraging Angle’s Parsortix platform for circulating tumor cell (CTC) capture. The partnership...
Molecular You Secures $5 Million to Expand Advanced Biomarker Testing
Consumer health company Molecular You completed a $5 million Series A round led by Voloridge Health to enhance its blood test platform analyzing over 250 biomarkers for 26 health conditions and...
Graphene Advances Neuronal Maturation and Stimulation in Brain Organoids
UC San Diego researchers have pioneered Graphene-Mediated Optical Stimulation (GraMOS), a novel technique using light to activate and mature neurons grown on graphene-coated substrates. The method...
FDA Appoints Stephen Hahn as CEO of Radiopharmaceuticals Startup Nucleus RadioPharma
Former FDA Commissioner Stephen Hahn has been named CEO of Nucleus RadioPharma, a contract developer and manufacturer specializing in radiopharmaceuticals and radioligand therapies. These...
Sarepta Triggers $100 Million Milestone with Arrowhead on Myotonic Dystrophy Program
Sarepta Therapeutics announced significant progress on its SRP-1003 siRNA candidate for Myotonic Dystrophy type 1 (DM1), activating a $100 million milestone payment to partner Arrowhead...
Viking Therapeutics Oral Obesity Drug Achieves Weight Loss but Faces High Discontinuations
Viking Therapeutics' oral GLP-1/GIP agonist VK-2735 demonstrated up to 12.2% weight loss in a phase 2 trial after 13 weeks. However, high gastrointestinal adverse events led to a 38%...
CSL Outlines Restructuring: Workforce Cuts and Seqirus Vaccine Unit Spin-Off
Australian pharmaceutical company CSL announced a strategic overhaul including a workforce reduction of up to 15% and the spin-off of its influenza vaccine business, Seqirus, into an independent...
Natera’s Signatera Test Identifies Bladder Cancer Patients Benefiting from Tecentriq Therapy
In the Phase III IMvigor011 trial, Natera’s Signatera circulating tumor DNA (ctDNA) test successfully stratified muscle-invasive bladder cancer patients regarding response to Genentech's Tecentriq...
VantAI and Halda Therapeutics Forge $1B+ Collaboration to Develop Proximity-Based Therapies
VantAI, an AI-driven protein interaction company spun out from Roivant Sciences, partnered with Halda Therapeutics in a deal exceeding $1 billion in potential value to accelerate discovery of...
Viking Therapeutics Oral Obesity Drug Faces Investor Concerns
Viking Therapeutics reported weight loss of up to 12.2% in a phase 2 trial of its oral GLP-1/GIP agonist VK-2735 after 13 weeks but was met with investor disappointment due to substantial...
Novo Nordisk’s Wegovy Expands to Fatty Liver Disease Treatment
The U.S. Food and Drug Administration granted accelerated approval for Novo Nordisk's GLP-1 agonist Wegovy (semaglutide) to treat metabolic dysfunction-associated steatohepatitis (MASH), a common...
Adaptive Biotechnologies and Genentech End Cancer Cell Therapy Collaboration
Adaptive Biotechnologies announced termination of its strategic partnership and licensing agreement with Genentech for developing personalized cancer cell therapies, effective February 2026. The...
FDA Delays and Rejections Impact Rare Disease and Gene Therapy Development
The FDA has delayed decisions on Regenxbio’s Hunter syndrome gene therapy and rejected PTC Therapeutics’ Friedreich’s ataxia drug vatiquinone, requesting further well-controlled studies. Stealth...
AI-Driven Innovations in Drug Delivery and Diagnostics
Researchers are advancing AI applications to accelerate RNA therapy development, improve mammogram interpretations, and design novel diagnostic platforms. MIT’s COMET model optimizes lipid...
Gene Editing and T-Cell Therapy Advances Against Cancer
Anocca AB raised $46 million to fund a phase I trial testing its CRISPR-edited T-cell receptor therapy targeting KRAS mutations in pancreatic cancer. Skyhawk Therapeutics secured a $2 billion...